New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household products that double as household names. Listing them all would require more space than is practical, but they include Band-Aid, Listerine, Splenda, Stayfree, Lubriderm, Visine, Purell, Mylanta, Bengay, and dozens upon dozens of others. If you’ve ever bandaged a wound, rinsed your mouth, applied lotion, moisturized your eyes, sanitized your hands, done battle with a headache, substituted for sugar or treated heartburn, chances are excellent that you did so courtesy of Johnson & Johnson’s research and development.

Johnson & Johnson’s array of consumer goods isn’t merely wide, but dominant. To quote company Chairman and CEO Alex Gorsky, “approximately 70% of our sales come from products with the number one or number two global market share position.” Johnson & Johnson boasts no fewer than 275 subsidiary companies, up from 250 three years ago. These include LifeScan, which makes blood glucose monitoring systems; McNeil Nutritionals, maker of artificial sweeteners; and Ethicon, a provider to the laparoscopic surgery industry.

Not Just Tylenol

But as omnipresent in the collective consciousness as Johnson & Johnson’s consumer goods are, the company is first and foremost a medical supplier. Two-fifths of Johnson & Johnson’s revenue derives from its medical devices, another two-fifths via pharmaceuticals. Johnson & Johnson’s preeminence in medical devices is particularly pronounced: the 70% sales figure for market-leading and market-runner-up products jumps to 85% when restricted to the company’s orthopedic instruments and surgical care items.

As for its global pharmaceutical business, Johnson & Johnson develops and sells some of the best-known over-the-counter drugs on the market. However, the true profit centers are the company’s higher-margin specialty pharmaceuticals. These include Remicade, Simponi, and Stelara, drugs that suppress autoimmune ailments (arthritis, Crohn’s disease) and that can cost more than $20,000 per year per patient; Zytiga, which fights particularly resilient forms of prostate cancer and which sells for $40 a pill; and Complera and Edurant, HIV drugs that can retail for over $70 per dose. These drugs might not be as ubiquitous as their fever-reducing brethren, but their contribution to Johnson & Johnson revenue is unmistakable. Given the slow pace of drug approval in both the United States and Europe, the profits realized by Johnson & Johnson today are the result of years and billions of dollars’ worth of research already undertaken. The company acknowledges that it files for approval for new drugs and line extensions of existing drugs up to 4 years in advance, and lag doesn’t even include how long it takes said drugs to then appear on pharmacy shelves.

Medical devices and diagnostics account for $29 billion of Johnson & Johnson’s global sales, putting that division just slightly ahead of the pharmaceutical one and making Johnson & Johnson the largest medical devices company on Earth. One doesn’t typically think of knee implants and catheters as carrying corporate brand names in the same way that shampoos or antihistamines do, but the former are every bit as much Johnson & Johnson products as the latter are. The only difference is the per-unit profitability. A Johnson & Johnson Attune knee replacement package can sell for around $10,000, not counting the price of professional surgical insertion, of course. With over 23,000 such packages now joining various thighs to lower legs around the world, it’s easy to see how just one specialty product can contribute to annual Johnson & Johnson revenues of over $71 billion.

Growth By Acquisition

Not all of the company’s revenue derives organically. In those instances where Johnson & Johnson doesn’t innovate in its crucial fields of interest, it instead uses its substantial financial muscle to acquire. In 2012 Johnson & Johnson finalized its $22 billion purchase of Synthes, which had been a publicly-traded Swiss manufacturer of implements that treat traumatic injuries. That was Johnson & Johnson’s largest purchase since it bought Pfizer’s (NYSE:PFE) consumer healthcare unit in 2006, which instantly positioned Johnson & Johnson as a certifiable consumer products titan.

But pharmaceutical and medical devices together account for only four-fifths of Johnson & Johnson revenue. The remainder derives from the aforementioned consumer products, and the lion’s share of that in the categories of over-the-counter medications and skin care. The company singles out anti-inflammatory drug Motrin and fever medication Tylenol for particular contributions to the bottom line. Worldwide sales of Tylenol exceeded $1.6 billion last year, making the painkiller the best-selling product of its kind.

The Bottom Line

Johnson & Johnson provides some of the most vital products in all of commerce; reducing the impact of AIDS, combating diabetes, even helping the deaf to hear and the lame to walk. Now well into its second century, Johnson & Johnson remains one of the most robust components of the Dow Jones Industrial Average, and one of the most influential and profitable companies in existence.

Related Articles
  1. Stock Analysis

    How Warren Buffett made Berkshire Hathaway a World-beater

    It would almost be easier to list the industry sectors in which Omaha-based Berkshire Hathaway Inc. (NYSE:BRK.A) doesn’t turn gargantuan profits.
  2. Investing Basics

    Conglomerates: Cash Cows Or Corporate Chaos?

    Huge companies may not be as infallible as previously assumed. Find out why bigger isn't always better.
  3. Investing News

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
  4. Investing News

    Big Pharma Faces 'Pay For Delay' Lawsuits

    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of planning to lose nearly all revenue once the drug goes off patent, the ...
  5. Bonds & Fixed Income

    Conglomerates: Risky Proposition?

    Investing in a corporate giant may not be as safe as you think.
  6. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  7. Investing

    Is Alphabet the Next Berkshire Hathaway?

    Google has made headlines for self-driving cars and biotech products, but the most profitable part of the business remains the advertising connected with its search engine.
  8. Mutual Funds & ETFs

    ETF Analysis: iShares US Medical Devices

    Learn about the iShares U.S. Medical Devices exchange-traded fund, its characteristics, suitability and recommendations for investors.
  9. Stock Analysis

    Warren Buffett's Latest Bet: The Riskiest Yet?

    Warren Buffett just made the biggest — and possibly riskiest — acquisition of his career.
  10. Investing News

    How Google's Transformation to Alphabet Will Impact Shareholders

    Google will retain search, ads, maps, apps, YouTube and Android, according to the company’s SEC filing, while Calico, Nest (interconnected thermostats and smoke detectors), Fiber (broadband and ...
RELATED TERMS
  1. Conglomerate

    A company that owns controlling stake in a number of smaller ...
  2. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
  3. Unbundling

    The process of taking over a large company with several different ...
  4. Divestiture

    The disposal of a business unit through sale, exchange, closure, ...
  5. Double Irish With A Dutch Sandwich

    A tax avoidance technique employed by certain large corporations, ...
  6. Associate Company

    A corporation whose parent company possesses only a minority ...
RELATED FAQS
  1. What debt/equity ratio is common for companies in the drugs sector?

    The average long-term debt-to-equity (D/E) ratio common for companies in the drugs sector is 70.66 based on trailing 12-month ... Read Full Answer >>
  2. What is the difference between a green field and a brown field investment?

    Green-field and brown-field investments are two different types of foreign direct investment, or FDI. Green-field investments ... Read Full Answer >>
  3. Why is the 1982 AT&T breakup considered one of the most successful spinoffs in history?

    AT&T had a history reaching back to 1885 and, as a government-supported monopoly, was a highly profitable company. Colloquially ... Read Full Answer >>
  4. What are the differences between affiliate, associate and subsidiary companies?

    All three of these terms refer to the degree of ownership that a parent company holds in another company. In most cases, ... Read Full Answer >>
  5. How do businesses decide whether to do FDI via green field investments or acquisitions?

    When businesses decide to expand their operations to another country, one of the more important dilemmas they can face is ... Read Full Answer >>
  6. Are domestic and foreign subsidiaries included on a company's financial statements?

    A subsidiary is a company that is controlled by another 'parent' company. The subsidiary acts and operates like its own entity ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!